Advantages of Chinese Medicine for Patients with Acquired Immunodeficiency Syndrome in Rural Central China

Qian-lei Xu; Hui-jun Guo; Yan-tao Jin; Jian Wang; Zi-qiang Jiang; Zheng-wei Li; Xiu-min Chen; Ying Liu; Li-ran Xu

doi:10.1007/s11655-017-2418-8

Your Location：

Home >

Browse articles >

Advantages of Chinese Medicine for Patients with Acquired Immunodeficiency Syndrome in Rural Central China

OriginalPaper | Updated：2021-08-27

- Advantages of Chinese Medicine for Patients with Acquired Immunodeficiency Syndrome in Rural Central China
- Advantages of Chinese Medicine for Patients with Acquired Immunodeficiency Syndrome in Rural Central China
- 中国结合医学杂志（英文版） 2018年24卷第12期页码：891-896
- Affiliations：
  
  1. Department of Acquired Immune Deficiency Syndrome Treatment and Research Center, the First Affiliated Hospital of Henan University of Traditional Chinese Medicine,Zhengzhou,China
  2. Henan Key Laboratory of Viral Diseases Control with Traditional Chinese Medicine,Zhengzhou,China
  3. Traditional Chinese Medicine Center for Acquired Immune Deficiency Syndrome Prevention and Treatment, China Academy of Traditional Chinese Medicine,Beijing,China
- Author bio：
- Funds：
  
  Supported by the National Natural Science Foundation of China (No. 81403342 and No. U1604287), the Science and Technology Program of Henan Province (No. 172102310325, No. 172102310199, No. 142102310511), the National Special Science and Technology Program on Major Infectious Diseases of China (2012ZX10005010-001) and Special of Scientific Research of Traditional Chinese Medicine of Henan Province in China (No. 2015ZY02097, No. 2016ZY2036, and No. 2015ZY01004)
- DOI：10.1007/s11655-017-2418-8
  中图分类号：
- 纸质出版日期：2018，
  
  网络出版日期：2017-9-8，
Scan for full text
Xu, Ql., Guo, Hj., Jin, Yt. et al. Advantages of Chinese Medicine for Patients with Acquired Immunodeficiency Syndrome in Rural Central China., Chin. J. Integr. Med. 24, 891–896 (2018). https://doi.org/10.1007/s11655-017-2418-8

Qian-lei Xu, Hui-jun Guo, Yan-tao Jin, et al. Advantages of Chinese Medicine for Patients with Acquired Immunodeficiency Syndrome in Rural Central China[J]. Chinese Journal of Integrative Medicine, 2018,24(12):891-896.
Xu, Ql., Guo, Hj., Jin, Yt. et al. Advantages of Chinese Medicine for Patients with Acquired Immunodeficiency Syndrome in Rural Central China., Chin. J. Integr. Med. 24, 891–896 (2018). https://doi.org/10.1007/s11655-017-2418-8 DOI：

Qian-lei Xu, Hui-jun Guo, Yan-tao Jin, et al. Advantages of Chinese Medicine for Patients with Acquired Immunodeficiency Syndrome in Rural Central China[J]. Chinese Journal of Integrative Medicine, 2018,24(12):891-896. DOI： 10.1007/s11655-017-2418-8.

摘要

To analyze the effect of Chinese medicine (CM) on mortality and quality of life (QOL) of acquired immunodefificiency syndrome (AIDS) patients treated with combined antiretroviral therapy (cART). A random sample of AIDS patients enrolled in the National Chinese Medicine Treatment Trial Program (NCMTP) that met the inclusion criteria was included in this study. NCMTP patients were included as the CM+cART group

and those not in the NCMTP were included as the cART group. Survival from September 2004 to September 2012 was analyzed by retrospective cohort study. QOL was analyzed by cross-sectional study. The retrospective cohort study included 528 AIDS patients

322 in the CM+cART group and 206 in the cART group. After 8 years

the mortality in the CM+cART group was 3.3/100 person-years

which was lower than the cART group of 5.3/100 person-years (P<0.05). The hazard ratio (HR) for mortality in the cART group was 1.6 times that of the CM+cART group by Cox proportional hazard model analysis. After controlling for gender

age

marital status

education

and CD4+ T-cell count

the HR was 1.9 times higher in the cART group compared with the CM+cART group (P<0.05). The cross-sectional study investigated 275 AIDS patients. The mean scores of all QOL domains except spirituality/personal beliefs were higher in the CM+cART group than in the cART group (P<0.05). For AIDS patients

CM could help to prolong life

decrease mortality

and improve QOL. However

there were limitations in the study

so prospective studies should be carried out to confifirm our primary results.

Abstract

322 in the CM+cART group and 206 in the cART group. After 8 years

the mortality in the CM+cART group was 3.3/100 person-years

age

marital status

education

and CD4+ T-cell count

CM could help to prolong life

decrease mortality

and improve QOL. However

there were limitations in the study

so prospective studies should be carried out to confifirm our primary results.

关键词

acquired immunodefificiency syndromemortalityquality of lifeChinese Medicine

Keywords

acquired immunodefificiency syndromemortalityquality of lifeChinese Medicine

references

Peter E, Kamath R, Andrews T, Hegde BM. Psychosocial determinants of health-related quality of life of people living with HIV/AIDS on antiretroviral therapy at Udupi District, Southern India. Int J Pre Med 2014;5:203–209.

Jin Y, Liu Z, Wang X, Liu H, Ding G, Su Y, et al. A systematic review of cohort studies of the quality of life in HIV/AIDS patients after antiretroviral therapy. Int J STD AIDS 2014;25:771–777.

Burgoyne RW, Tan DH. Prolongation and quality of life for HIV-infected adults treated with highly active antiretroviral therapy (HAART): a balancing act. J Antimicrob Chemother 2008;61:469–473.

Eron J, Yeni P, Gathe J, Estrada V, Delesus E, Staszewski S, et al. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomized non-inferiority trial. Lancet 2006;368:476–482.

Malan DR, Krantz E, David N, Yang R, Mathew M, Iloeje UH, et al. 96-week efficacy and safety of atazanavir, with and without ritonavir, in a haart regimen in treatment-naive patients. J Int Assoc Physicians AIDS Care 2010;9:34–42.

Chen Z. On the establishment of modern medical system of assimilating advantages of Oriental medicine and Western medicine. Chin J Integr Med 2014;20:323–325.

Liu ZB, Wang X, Liu HJ, Jin YT, Guo HJ, Jiang ZQ, et al. Treatment of acquired immunodeficiency syndrome with Chinese medicine in China: opportunity, advancement and challenges. Chin J Integr Med 2013;19:563–567.

Sun X, Wang N, Li D, Zheng X, Qu S, Wang L, et al. The development of HIV/AIDS surveillance in China. AIDS 2007;21:S33–S38.

Na H, Detels R. The HIV epidemic in China: history, response, and challenge. Cell Res 2005;15:825–832.

Wu Z, Sullivan SG, Wang Y, Rotheram-Borus MJ, Detels R. Evolution of China's response to HIV/AIDS. Lancet 2007;369:679–690.

Ministry of Health of the People's Republic of China. 2012 China AIDS Response Progress Report. Ministry of Health of the People's Republic of China. Available at: http://www.unaids.org/en/dataanalysis/knowyourresponse/countryprogressreports/2012countries/ce_CN_Narrative_Report[1].pdf. Accessed 14 October 2013.

Xu LR, Guo HJ, Liu ZB, Li Q, Yang JP, He Y. Unifiedplanning, graded-administration, and centralized controlling: a management modality for treating acquired immune deficiency syndrome with Chinese medicine in Henan Province of China. Chin J Integr Med 2015;21:243–248.

Editor Group. Handbook of China's free ART program. 3rd ed. Beijing: People's Medical Publishing House; 2012:14-58.

Hsiung PC, Fang CT, Chang YY, Wangle JD. Comparison of WHOQOL-bREF and SF-36 in patients with HIV infection. Qual Life Res 2005;14:141–150.

Yang YC, Duan S, Xiang LF, Ye RH, Gong YR, Yang SJ, et al. Study on the mortality and risk factors among HIV-infected individuals during 1989–2011 in Dehong prefecture, Yunnan Province. Chin J Epidemiol (Chin) 2012;33:1026–1030.

Sun DY, Wang Q, Yang WJ, Zhu Q, Wang Z. Survival analysis on AIDS antiretroviral therapy in Henan province during 2003–2009. Chin J Epidemiol (Chin) 2012;33:181–184.

Allam RR, Murhekar MV, Bhatnagar T, Uthappa CK, Chava N, Rewari BB, et al. Survival probability and predictors of mortality and retention in care among patients enrolled for first-line antiretroviral therapy, Andhra Pradesh, India, 2008–2011. Trans R Soc Trop Med Hyg 2014;108:198–205.

Jaquet A, Garanet F, Balestre E, Ekouevi DK, Azani JC, Bognounou R, et al. Antiretroviral treatment and quality of life in Africans living with HIV: 12-month follow-up in Burkina Faso. J Int AIDS Soc 2013;16:18867.

McManus H, O'Connor CC, Boyd M, Broom J, Russell D, Watson K, et al. Long-term survival in HIV positive patients with up to 15 Years of antiretroviral therapy. PLoS One 2012;7:e48839.

Skevington SM, Lotfy M, O'Connell KA. The World Health Organization's WHOQOL-BREF quality of life assessment: psychometric properties and results of the international field trial. A report from the WHOQOL group. Qual Life Res 2004;13:299–310.

Tran BX. Quality of life outcomes of antiretroviral treatment for HIV/AIDS patients in Vietnam. PLoS One 2012;7:e41062.

Dou Z, Chen RY, Wang Z, Ji G, Peng G, Qiao X, et al. HIV-infected former plasma donors in rural Central China: from infection to survival outcomes, 1985–2008. PLoS One 2010;5:e13737.

FULL TEXT LINK

More>

浏览量

Downloads

CSCD

文章被引用时，请邮件提醒。

Submit

工具集

关联资源

Standardized treatment of chinese medicine decoction for cancer pain patients with opioid-induced constipation: A multi-center prospective randomized controlled study

Effectiveness of Bufei Yishen Granule (补肺益肾颗粒) combined with acupoint sticking therapy on quality of life in patients with stable chronic obstructive pulmonary disease

Chinese medicine improves postoperative quality of life in endometriosis patients: A randomized controlled trial

Effect of Feitai Capsule (肺泰胶囊) on quality of life and progression-free survival of patients with unresectable non-small cell lung cancer

Effect of traditional and integrative regimens on quality of life and early renal impairment in elderly patients with isolated systolic hypertension